Bimekizumab

BIMZELX

Open Bimekizumab in the interactive console ↗

What it isIL-17A and IL-17F antibody; psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa.

Why this oneBlocking both IL-17A and F gives higher skin clearance rates than IL-17A blockade alone.

What limits itCandidiasis rises with the dual block — the price of the added efficacy. Screen for tuberculosis and inflammatory bowel disease.

FDA-approved for

Plaque psoriasis (2023)
Psoriatic arthritis (2024)
Ankylosing spondylitis (2024)
Hidradenitis suppurativa (2024)

FDA label

Read the full label on DailyMed ↗

FDA dosing	Population	Start	Target	Max
Moderate-to-severe plaque psoriasis	Adults	320 mg SC at Weeks 0, 4, 8, 12, 16	320 mg q8wk (>=120 kg: consider 320 mg q4wk after Wk 16)	320 mg q4wk
Active psoriatic arthritis	Adults (use psoriasis dosing if coexisting moderate-severe PsO)	160 mg SC q4wk	160 mg q4wk	160 mg q4wk
Non-radiographic axial spondyloarthritis	Adults	160 mg SC q4wk	160 mg q4wk	160 mg q4wk
Ankylosing spondylitis	Adults	160 mg SC q4wk	160 mg q4wk	160 mg q4wk
Moderate-to-severe hidradenitis suppurativa	Adults	320 mg SC at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16	320 mg q4wk	320 mg q4wk

Renal Undefined

Hepatic Undefined

Instructions

Subcutaneous injection; may self-inject after training
Before use, allow to reach room temperature (30-45 min)
Rotate injection sites; give two 160 mg injections at different sites
Evaluate for TB and test liver enzymes/ALP/bilirubin before initiation; complete age-appropriate vaccinations
Avoid live vaccines during treatment

Cautions

Suicidal ideation and behavior
Infections (withhold until resolved)
Tuberculosis (treat latent TB first; avoid in active TB)
Liver biochemical abnormalities
Inflammatory bowel disease
Avoid live vaccines

Adverse reactions

Upper respiratory tract infections
Oral candidiasis
Headache
Injection site reactions

Pregnancy Insufficient human data; human IgG crosses the placenta (peaks 3rd trimester); consider delaying live vaccines in infants exposed in utero.

Lactation No data on presence in human milk; endogenous IgG/monoclonal antibodies are transferred in human milk.

NO BOXED WARNINGS

Principal riskCandidiasis, higher than with IL-17A blockade alone